AR065928A1 - Docetaxel cristalino anhidro estable y metodo para la preparacion del mismo - Google Patents
Docetaxel cristalino anhidro estable y metodo para la preparacion del mismoInfo
- Publication number
- AR065928A1 AR065928A1 ARP080101384A ARP080101384A AR065928A1 AR 065928 A1 AR065928 A1 AR 065928A1 AR P080101384 A ARP080101384 A AR P080101384A AR P080101384 A ARP080101384 A AR P080101384A AR 065928 A1 AR065928 A1 AR 065928A1
- Authority
- AR
- Argentina
- Prior art keywords
- intensity
- docetaxel
- peak
- anhydrous crystalline
- crystalline form
- Prior art date
Links
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title abstract 6
- 229960003668 docetaxel Drugs 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- 238000002441 X-ray diffraction Methods 0.000 abstract 3
- 238000001228 spectrum Methods 0.000 abstract 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 230000000719 anti-leukaemic effect Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- -1 t-butoxycarbonyl Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
Abstract
La presente provee un docetaxel cristalino anhidro estable que tiene actividad antitumoral y antileucémica, y un método para la preparacion del mismo. Reivindicacion 1: Una forma cristalina anhidra de docetaxel caracterizada porque es de formula (1), en donde, Ph es fenilo; Ac es acetilo; Bz es benzoilo; y Boc es t-butoxicarbonilo. Reivindicacion 3: La forma cristalina anhidra de docetaxel de la reivindicacion 1, caracterizada porque su espectro de difraccion de rayos X muestra picos mayores que tienen una intensidad de pico relativa (100xI/II0; I: la intensidad del pico, I0: la intensidad del pico máximo) de al menos 100% a valores 2 theta de 4,88; 9,22; 9,72; 10,38; 11,30; 11,88; 13,34; 14,56; 15,14; 16,62; 17,28; 17,66; 19,02; 19,62; 19,86; 20,86; 21,86; 24,58; y 26,98. Reivindicacion 4: La forma cristalina anhidra de docetaxel de la reivindicacion 1, caracterizada porque su espectro de difraccion de rayos X muestra picos mayores que tienen una intensidad de pico relativa (100xI/I0 I: la intensidad del pico, I0: la intensidad del pico máximo) de al menos 55 % a valores 2theta de 4,62; 8,22; 9,20; 10;64; 11,44; 12,42; 13,80; 14,20; 15,28; 17,28; 18,46; 20,62; y 21,86. Reivindicacion 5: La forma cristalina anhidra de docetaxel de la reivindicacion 1, caracterizada porque su espectro de difraccion de rayos X muestra picos mayores que tienen una intensidad de pico relativa (100xI/I0; I: la intensidad del pico, l0: la intensidad del pico máximo) de al menos 50 % a valores 2theta de 4,06; 4,82; 7,58; 8,20; 9,84; 11,44; 12,76; 13,62; 14,16; 16,98; 19,18; 19,60; y 19,90.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020070035065A KR100878455B1 (ko) | 2007-04-10 | 2007-04-10 | 안정한 무수결정형 도세탁셀 및 이의 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065928A1 true AR065928A1 (es) | 2009-07-08 |
Family
ID=39831157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101384A AR065928A1 (es) | 2007-04-10 | 2008-04-03 | Docetaxel cristalino anhidro estable y metodo para la preparacion del mismo |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100099897A1 (es) |
| EP (1) | EP2155709A4 (es) |
| JP (1) | JP2010523647A (es) |
| KR (1) | KR100878455B1 (es) |
| CN (1) | CN101652356A (es) |
| AR (1) | AR065928A1 (es) |
| CL (1) | CL2008000980A1 (es) |
| PE (1) | PE20090045A1 (es) |
| TW (1) | TW200906813A (es) |
| WO (1) | WO2008123751A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1891143B1 (en) | 2005-06-06 | 2012-01-11 | The University Of British Columbia | Polymer-based serum albumin substitute |
| KR101149600B1 (ko) * | 2009-12-31 | 2012-05-29 | 주식회사 삼양제넥스바이오 | 고순도 무수결정형 도세탁셀 제조방법 |
| US9186410B2 (en) | 2010-03-01 | 2015-11-17 | The University Of British Columbia | Derivatized hyperbranched polyglycerols |
| JP5824511B2 (ja) | 2010-05-03 | 2015-11-25 | テイコク ファーマ ユーエスエー インコーポレーテッド | 非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法 |
| US8842114B1 (en) | 2011-04-29 | 2014-09-23 | Nvidia Corporation | System, method, and computer program product for adjusting a depth of displayed objects within a region of a display |
| JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
| CN107683134B (zh) | 2015-05-15 | 2021-02-23 | 珠海贝海生物技术有限公司 | 多西他赛及人血清白蛋白复合物 |
| CN110062622B (zh) | 2016-10-27 | 2022-10-14 | 珠海贝海生物技术有限公司 | 多西他赛和人血清白蛋白的中性pH组合物 |
| CN115297857B (zh) | 2020-02-04 | 2024-07-19 | 珠海贝海生物技术有限公司 | 多西他赛制剂 |
| US20250152551A1 (en) | 2022-02-25 | 2025-05-15 | Zhuhai Beihai Biotech Co., Ltd. | Docetaxel compositions and methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2722191B1 (fr) | 1994-07-08 | 1996-08-23 | Rhone Poulenc Rorer Sa | Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle |
| EP1497275A4 (en) * | 2002-04-05 | 2006-04-12 | Natural Pharmaceuticals Inc | SELECTIVE ACYLATION OF SECONDARY HYDROXYL GROUPS |
| US6838569B2 (en) * | 2002-12-16 | 2005-01-04 | Dabur India Limited | Process for preparation of paclitaxel trihydrate and docetaxel trihydrate |
| WO2005061474A1 (en) * | 2003-12-12 | 2005-07-07 | Quiral Química Do Brasil | Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions |
| FR2864340B1 (fr) * | 2003-12-19 | 2006-03-24 | Commissariat Energie Atomique | Microcomposant comportant une microcavite hermetique et procede de fabrication d'un tel microcomposant |
| CN100420681C (zh) | 2005-04-29 | 2008-09-24 | 上海奥锐特国际贸易有限公司 | 多烯紫杉醇三水物的制备方法 |
| KR20070088784A (ko) * | 2005-10-12 | 2007-08-29 | 시코르, 인크. | 도세탁셀의 결정형 및 이의 제조 방법 |
| KR100995390B1 (ko) * | 2006-01-02 | 2010-11-19 | 주식회사 삼양제넥스 | 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법 |
| BRPI0600194A (pt) * | 2006-01-30 | 2007-10-23 | Quiral Quimica Do Brasil S A | composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas |
| CN101534642A (zh) * | 2006-10-20 | 2009-09-16 | 神隆药业新加坡私人有限公司 | 用于制备结晶无水多西紫杉醇的方法 |
-
2007
- 2007-04-10 KR KR1020070035065A patent/KR100878455B1/ko not_active Expired - Fee Related
-
2008
- 2008-04-03 AR ARP080101384A patent/AR065928A1/es not_active Application Discontinuation
- 2008-04-04 CL CL200800980A patent/CL2008000980A1/es unknown
- 2008-04-09 PE PE2008000630A patent/PE20090045A1/es not_active Application Discontinuation
- 2008-04-09 TW TW097112817A patent/TW200906813A/zh unknown
- 2008-04-10 EP EP08741259A patent/EP2155709A4/en not_active Withdrawn
- 2008-04-10 CN CN200880011306A patent/CN101652356A/zh active Pending
- 2008-04-10 JP JP2010502936A patent/JP2010523647A/ja not_active Withdrawn
- 2008-04-10 US US12/532,887 patent/US20100099897A1/en not_active Abandoned
- 2008-04-10 WO PCT/KR2008/002014 patent/WO2008123751A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008123751A1 (en) | 2008-10-16 |
| KR100878455B1 (ko) | 2009-01-13 |
| JP2010523647A (ja) | 2010-07-15 |
| KR20080091945A (ko) | 2008-10-15 |
| EP2155709A4 (en) | 2010-09-15 |
| EP2155709A1 (en) | 2010-02-24 |
| CL2008000980A1 (es) | 2008-08-22 |
| PE20090045A1 (es) | 2009-03-22 |
| US20100099897A1 (en) | 2010-04-22 |
| TW200906813A (en) | 2009-02-16 |
| CN101652356A (zh) | 2010-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065928A1 (es) | Docetaxel cristalino anhidro estable y metodo para la preparacion del mismo | |
| CY1118649T1 (el) | Συσκευη παραγωγης πλασματος και χρηση της συσκευης παραγωγης πλασματος | |
| MY176680A (en) | Cyclic amides as metap-2 inhibitors | |
| AR096759A1 (es) | Formas sólidas de un inhibidor de quinasa macrocíclica | |
| CY1118129T1 (el) | 5-αλκυνυλ-πυριμιδινες | |
| CO6251311A2 (es) | Proceso para la preparacion de acido 5-bifenil-4-amino-2-metil pentanoico | |
| UA111770C2 (uk) | Інгібітори бромдомену | |
| CY1118771T1 (el) | Μακροκυκλικα παραγωγα για την αγωγη υπερπλαστικων παθησεων | |
| EA201491623A1 (ru) | Замещенные пирролидин-2-карбоксамиды | |
| CY1116436T1 (el) | Αλατα και πολυμορφα μιας ενωσης τετρακυκλινης | |
| ES2722629T3 (es) | Una composición de tamiz molecular novedosa, un método de elaboración y un proceso de uso de la misma | |
| MX367367B (es) | Sales de arginina y sus usos para el tratamiento de enfermedades en la cavidad oral. | |
| CY1117752T1 (el) | Τετρακυκλικη ενωση | |
| EP4104114A4 (en) | Hybrid quantum-classical adversarial generator | |
| EA200901250A1 (ru) | Сульфониламидные производные для лечения аномального роста клеток | |
| EA201492166A1 (ru) | N-замещенные бензамиды и их применение в лечении боли | |
| EA201391602A1 (ru) | Контролируемое высвобождение иммунодепрессантов из синтетических наноносителей | |
| TR200906329T1 (tr) | Kanser Hastalarında Kemik Gelişimini Desteklemek için A | |
| EA201401062A1 (ru) | Бициклические пиразиноновые производные | |
| MX2014008640A (es) | Composiciones farmaceuticas y metodos. | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| EA201390988A1 (ru) | Фенантридиновые макроциклические ингибиторы сериновой протеазы вируса гепатита c | |
| GT200600280A (es) | Composiciones y metodos para el tratamiento de sintomas relacionados con el ciclo | |
| TR201910685T4 (tr) | Bir inaktive RGD bölgesine sahip modifiye osteopontin peptitleri ve bunların kullanımları. | |
| EA201170425A1 (ru) | Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |